| Description: |
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent, potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle blocking, apoptosis, or autophagy in acute myeloid leukemia. |
| Stability and Solubility Advice: |
Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details. |
